CD Protein Inhibitors News

«1 2...83 84 85 86 878889 90 91 92 93...3932 3933 »

|||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Tyrosine Kinase Inhibitors (Alone or in Combination) for the Management of Advanced Thymic Epithelial Tumors (TETs) Among Hispanics (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2451;
Earlier treatment lines favored better PFS, with patients treated with TKI as a fourth line reaching a median of 1.28 months compared to 5.97 months as a second and 6.33 months as a third line (p<0.001). Conclusions : These findings suggest that TKIs are efficacious as second or post-line treatments and represent a viable treatment option for Hispanic patients with advanced TETs.

|||||||||| With Eyes on the Future: Prospective Evaluation of Immune-Related Adverse Events in Patients with Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2438;
Though nausea and abdominal pain were less common, when present, these symptoms were reported with high severity. Future data from this study will elucidate patient experiences with irAEs throughout their treatment course.

|||||||||| Tecentriq (atezolizumab) / Roche
LCMC3: Clinical Utility of Suvmax on Preoperative 18F-FDG PET-CT in Resectable NSCLC Treated with Neoadjuvant Atezolizumab (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2433;
P2
Conclusions : Decreasing vs increasing SUVmax following neoadjuvant atezolizumab treatment was associated with improved clinical outcomes, including a trend toward longer DFS and significant improvements in major pathologic response and overall survival. These results suggest that assessment of SUVmax may be a valuable tool for clinicians that should be further evaluated for pre-surgery prognostic stratification of patients with resectable NSCLC.

|||||||||| Imfinzi (durvalumab) / AstraZeneca
Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-Small Cell Lung Cancer (NSCLC) (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2402;
No new safety signals were seen with the addition of a single dose of induction D prior to chemoradiation and consolidation D. The initial 12-month PFS of 30% is disappointing, although not statistically significant as intended to compare with historical control. Interestingly, all 3 pts progression-free at 12 months had high TMB, without apparent relation to PD-L1 status.

|||||||||| Imfinzi (durvalumab) / AstraZeneca
Survival after Salvage Treatment Following Durvalumab Consolidation in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2401;
Table 1. Treatment Category Patients (n) Median Mos from Durvalumab Start to Subsequent Therapy (IQR) Median Mos from Durvalumab End to Subsequent Therapy (IQR) Median Overall Survival from Start of Post-durvalumab Therapy, mos (IQR) Chemotherapy 349 8.0 (4.4-13.0) 1.8 (0.9-5.2) 10.8 (5.6-18.8) Chemotherapy + PD-(L)1 147 8.3 (3.9-17.7) 1.5 (0.9-7.2) 12.9 (6.0-24.2) PD-(L)1 monotherapy 114 14.2 (6.2-20.8) 3.3 (1.4-11.6) 23.8 (8.7-34.5) PD-(L)1+CTLA4 37 14.0 (8.5-21.9) 5.5 (1.7-13.2) 12.7 (4.5-20.7) Targeted Therapy 104 7.6 (5.0-13.7) 1.9 (1.0-4.9) 30.1 (9.5-NR)

|||||||||| Imfinzi (durvalumab) / AstraZeneca
The Efficacy of Durvalumab after Concurrent Chemoradiotherapy for EGFR-Mutated Stage III Non-Small Cell Lung Cancer (NEJ063) (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2400;
There were no differences in the frequency of adverse events ?CTCAE grade 3 of subsequent EGFR-TKIs between both groups (27.8% vs 26.0%, p=1.0). Conclusions : In our real-world data for EGFR-mutated stage III NSCLC, durvalumab after CCRT improved PFS and did not increase the frequency of adverse events ?CTCAE grade 3 of subsequent EGFR-TKI compared with CRT alone.

|||||||||| Imfinzi (durvalumab) / AstraZeneca
Circulating T-Cell Immunosenescence in Patients with Unresectable Locally Advanced NSCLC: Preliminary Results of the SENLOAD Study (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2398;
P1
Introduction : Standard of care for patients with unresectable locally advanced (LA) non-small cell lung cancer (NSCLC) is concomitant platinum-based chemotherapy radiotherapy (CTRT) followed by anti-PD-L1 immune checkpoint blocker (ICB) durvalumab consolidation...Assessment of Immunosenescence profile in stage III-NSCLC treatment strategy may contribute to improve personalization but did not seem related to toxicity. Further analyses are expected.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD), Tecentriq (atezolizumab) / Roche
Cost-Effectiveness of PD-L1 Testing for Guiding Immunotherapy in Non-Small Cell Lung Cancer (Stage IIA-IIIB & Stage IV) Patients in China (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2352;
Conclusions : In China, the SP263 PD-L1 testing is the most cost-effective option for guiding immunotherapy in both stage IIA-IIIB and stage IV NSCLC patients. Cost-Effectiveness Analysis Results

|||||||||| Imfinzi (durvalumab) / AstraZeneca
Diagnostic and Treatment Gaps in NSCLC Management Compared to NCCN Recommendations: An Audit Analysis of 214 Cases. (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2329;
Durvalumab was not used in any patient (79 DM)...All major deviations are associated with survival advantage in clinical trials. Most common reason was lack of financial support and non-availability of the modality.

|||||||||| Avastin (bevacizumab) / Roche, Kaitanni (cadonilimab) / Akesobio
Cadonilimab Plus Bevacizumab and Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma: A Single-Arm Phase II Study (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2297;
P2
The immunotherapies nivolumab and ipilimumab improved survival compared with platinum-pemetrexed, particularly in non-epithelioid histology...Patients will receive carboplatin AUC 5, pemetrexed 500 mg/m2, bevacizumab 7.5 mg/kg, cadonilimab 10 mg/kg intravenously on day 1 of a 3-weekly schedule for a maximum of six cycles...A total of 38 patients will be recruited to account for dropout. Enrolment began in November 2023 and the study is currently ongoing.

|||||||||| Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Clinical Insights and Survival Outcomes of Malignant Pleural Mesothelioma: An Experience from a Tertiary Care Centre in India (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2278;
Of 25 patients 18 (72%) received systemic chemotherapy, with pemetrexed-platinum (either cis- or carbo-platin)...10 patients received subsequent lines of systemic therapy which included immunotherapy (nivolumab + ipilimumab), gemcitabine (with or without bevacizumab) and oral metronomic therapy (containing cyclophosphamide, etoposide and pazopanib)...Conclusions : With the response rates of 44.4% and median survival of 26 months, the outcomes of systemic therapy in MPM are comparable with the global population. Given the aggressive nature and grim prognosis of the disease, it is imperative to advance our comprehension of its biology and treatment efficacy factors.

|||||||||| Gilotrif (afatinib) / Boehringer Ingelheim, Tecentriq (atezolizumab) / Roche
Genetic Landscape and Prognostic Markers of Small Cell Lung Cancer: A Comprehensive Study (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2260;
Patient 3 demonstrated MYC amp loss following etoposide and afatinib therapy. Conclusions : This study provides insights into the gene profile and prognosis of SCLC in Chinese patients, emphasizing the importance of understanding ethnic variations and individualizing treatment strategies.

|||||||||| Tecentriq (atezolizumab) / Roche
Impact of Antiemetic Steroid Use on Survival in Small Cell Lung Cancer Patients with Immune Checkpoint Inhibitors and Chemotherapy Combination (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2252;
The study estimated the use of antiemetic steroids, specifically dexamethasone, within a 4-day window following chemotherapy administration...However, the total administration of larger dosages of steroids, including for purposes other than antiemetics can significantly affect outcomes. Further investigation is warranted to explore the nuances of steroid use in cancer therapy.

|||||||||| Imfinzi (durvalumab) / AstraZeneca, Neulasta (pegfilgrastim) / Roche, Tecentriq (atezolizumab) / Roche
The Conflicting Impacts of G-CSF on the Therapeutic Efficacy of Chemoimmunotherapy for Extensive Stage Small Cell Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2249;
Methods : We selected 65 patients with ES-SCLC who completed four cycles of induction chemo-immunotherapy (atezolizumab or durvalumab combined with carboplatin plus etoposide) in Tokushima University Hospital and four affiliated hospitals between January 2019 and July 2022...G-CSF administration was defined as the following classifications in this study; Classification A: use of any G-CSF (at least one dose of either filgrastim or pegfilgrastim), Classification B: use of at least one dose of pegfilgrastim, and Classification C: use of either more than five doses of filgrastim or at least one dose of pegfilgrastim...Similar results were observed in the other classifications. Conclusions : Our study suggests that the indication of G-CSF administration during chemo-immunotherapy should be carefully considered to avoid attenuating the therapeutic efficacy of chemo-immunotherapy in the patients with ES-SCLC.

|||||||||| Hansizhuang (serplulimab) / Fosun Pharma, Tecentriq (atezolizumab) / Roche
Radiotherapy Combined with Immunotherapy in the Treatment of Brain Metastases from Small Cell Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2234;
In the synchronized group compared with the asynchronized group, PFS (P=0.013) and iPFS (P=0.029) had a significant advantage.The rest of the main therapeutic indexes and the incidence rate of adverse reactions did not show any statistically significant differences. Conclusions : Under the premise of universal use of chemotherapy, ICI+BRT as the first-line therapy for patients with baseline ES-SCLC brain metastases has better efficacy than ICI or BRT alone.There is a trend that ICI asynchronous BRT therapy is superior to ICI synchronous BRT therapy.

|||||||||| Cosela (trilaciclib) / G1 Therap
Evaluation of Trilaciclib Use and Chemotherapy Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2233;
Conclusions : Early real-world outcomes following treatment with trilaciclib suggest a potential reduction in myelosuppressive HAE among patients with ES-SCLC who receive platinum/etoposide-containing regimen or topotecan-containing regimen. However, limitations to this study include its retrospective study design, small sample size, and that analysis for the two cohorts involved two different time frames.

|||||||||| etoposide oral / Generic mfg.
Extensive Small Cell Lung Cancer (SCLC): Maintenance Oral Etoposide Daily for 6 Days Every 3-4 Weeks Until Tumor Progression (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2232;
Alternatively, it might have arisen from change of etoposide to a potentially less effective 4-week schedule from a 3-week schedule when durvalumab is used. We have initiated assessment of maintenance oral etoposide with atezolizumab (3-week schedule), which has comparable efficacy to durvalumab.

|||||||||| Tecentriq (atezolizumab) / Roche
Efficacy and Safety Analysis of Atezolizumab Continuation Beyond Progression in Extensive Small Cell Lung Cancer(ES-SCLC) (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2231;
Conclusions : The continuing immunotherapy combination therapy demonstrated favorable response in patients who experienced progression following 1L immunotherapy, especially for those who achieved PFS more than six months in 1L treatment. Additionally, combined radiotherapy during the immunotherapy continuation treatment can bring PFS benefit.

|||||||||| Clinical Outcomes of Continuous Immunotherapy Beyond Progression in Patients with Extensive-Stage Small Cell Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2226;
Seventy-eight patients received PD-L1 antibody including atezolizumab, durvalumab, adebrelimab and envafolimab, while 19 patients received PD-1 antibody including pembrolizumab, serplulimab and tislelizumab...The second-line PFS of 23 patients receiving anti-angiogenic therapy such as anlotinib and sorafenib (14 in combination with immunotherapy or immunochemotherapy and 9 in combination with chemotherapy) was 5.3 months (95%CI: 3.5-7.1), indicating combined anti-angiogenic therapy may yield better survival benefit for ES-SCLC patients treated with first-line immunochemotherapy...Anti-angiogenic agent containing strategy may further improved survival after first-line immunochemotherapy. The long-term efficacy is still under follow-up.

|||||||||| Imfinzi (durvalumab) / AstraZeneca, Tecentriq (atezolizumab) / Roche
Real-World Outcomes of Platinum-immunotherapy as First-Line (1L) Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2225;
Consistent with previous findings, less frequent AESIs and better prognostic factors were observed in the maintenance subgroup. The modest OS in this study underscores the unmet need for effective 1L treatment to improve survival for ES-SCLC.

|||||||||| Tecentriq (atezolizumab) / Roche
Real-World Insights: Treatment Patterns and Overall Survival in Patients with Small-Cell Lung Cancer in South Korea a Single Center Experience (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2223;
As a subsequent therapy, paclitaxel was the most common for ES (64/97, 66.0%) and LS (12/32, 37.5%) patients...Conclusions : Our findings confirm once again the poor survival outcomes in SCLC. Results highlight the limitations of current treatment and underscore the urgent need for effective therapeutic strategies to improve this challenge.

|||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
Selection of Optimal Therapy for Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2221;
Conclusions : To the best of our knowledge, this NMA demonstrated for the first time that adding anlotinib and benmelstobart to chemotherapy significantly improved PFS and OS compared with chemotherapy alone or chemotherapy plus immunotherapy, with an acceptable safety profile in patients with ES-SCLC. In conclusion, Anl/Ben/CT could be a new and clinically preferable first-line treatment option for this population.

|||||||||| Tecentriq (atezolizumab) / Roche
Prognostic Laboratory Parameters in Imfirst: Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2219;
P3
Conclusions : This exploratory analysis from IMfirst, although limited due to the single-arm nature of the study, suggests biochemical and haematological parameters of potential prognostic value in ES-SCLC patients treated with atezolizumab + chemotherapy. Further validation in prospective studies is required.

|||||||||| Ariely (adebrelimab) / Jiangsu Hengrui Pharma, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Adebrelimab Combined with Famitinib and Chemotherapy as First-Line Therapy for ES-SCLC: A Phase II, Single-Arm Exploratory Research (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2216;
The primary endpoint is 6-month progress-free survival (6-month PFS) rate, and the secondary endpoints are objective response rate, disease control rate, 12-month PFS, PFS, overall survival, safety and quality of life. The study is actively recruiting.

|||||||||| Ariely (adebrelimab) / Jiangsu Hengrui Pharma, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Preliminary Efficacy and Safety of Adebrelimab Plus Famitinib as Later-line Treatment for Extensive-Stage Small Cell Lung Cancer: A Phase 2 Trial (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2215;
A Simon two-stage design was applied. If there were more than 1 patient achieved response within the first 13 pts, the cohort would expand to 34 pts.

|||||||||| BAY 2927088 / Bayer, Broad Institute
SOHO-02: Phase III Trial of BAY 2927088 In Patients with Locally Advanced or Metastatic NSCLC with HER2-Activating Mutations (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2213;
Overall, 278 eligible patients will be randomized to oral BAY 2927088 (20 mg twice daily) or standard of care (SoC; pembrolizumab in combination with platinum-based chemotherapy [cisplatin or carboplatin] and pemetrexed) administered in 21-day cycles. Patients

|||||||||| Rybrevant (amivantamab-vmjw) / J&J, cetrelimab (JNJ-63723283) / J&J
Amivantamab, An EGFR-MET Bispecific Antibody, with Cetrelimab, An Anti-PD-1 Antibody, In Advanced NSCLC: Phase 1/2 Polydamas (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2207;
P1/2
In both phases, patients will continue study treatment until disease progression, unacceptable toxicity, or until another criterion for treatment discontinuation is met. This study is currently enrolling, with an enrollment goal of 80 patients total.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD), Tecentriq (atezolizumab) / Roche
Real-World Biomarker Testing and Treatment Patterns for Locally Advanced and Metastatic Non-Small Cell Lung Cancer in Canada (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2204;
Conclusions : In Canada, most patients do not receive complete testing for AGAs, highlighting the need for improved access to biomarker testing. Only 69% of patients with an AGA received a targeted therapy by their 2LOT and 59% of patients without AGAs received ICI +/- chemotherapy in 1L, indicating an unmet need for increased use of guideline recommended systemic therapies.

|||||||||| Lorbrena (lorlatinib) / Pfizer
Platinum-Pemetrexed Chemotherapy and Lorlatinib Combination in Advanced ALK Positive NSCLC Progressing to Lorlatinib: A Case Series (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2176;
Conclusions : This is the first proof of efficacy and safety of PT/PEM-based-CT and lorlatinib combination after lorlatinib failure in advanced in ALK+ NSCLC. To confirm this evidence, we developed a prospective, multicenter, phase II trial combining PT/PEM-based-CT and lorlatinib for the treatment of ALK+ NSCLC pts extracranially progressed on lorlatinib

|||||||||| Orpathys (savolitinib) / AstraZeneca, Hutchmed
Durable Response to Savolitinib in Advanced EGFR-WT NSCLC with MET Amplification: Case Series (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2154;
Further data from larger cohorts and longer follow-up are needed to confirm these findings. Table: Case series chart of four patients Patient case Sex Age Smoking History T NM stage Metastases MET CN IHC Concurrent mutation Prior treatment Regimen Response Adverse events 1 Male 52 Yes cT4N3M1c Bones, adrenal gland 14 M ET IHC 3+ (90%) , PD-L 1 positive ( TPS:60% + ) TP53 mutation None Savolitinib monotherapy PR, ongoing None reported 2 Male 75 Yes cT1cN0M1c Bone 17.1 M ET IHC 2+ (100%) , PD-L1 positive ( TPS:80%+) TP53 mutation; ARID1A mutation; KMT2D mutation; RICTOR amplification; RICTOR mutation None Savolitinib monotherapy PR, ongoing None reported 3 Female 67 No cT4N3M1c Brain 1.6(1 st -line )4.1 (re-biopsy) Re-biopsy: M ET IHC 3+ (100%) , PD-L1 positive (TPS:45%+) NTRK fusion; TP53 mutation; PIK3CA mutation; FGFR1 a mplication; ATM mutation; RICTOR mutation; Entrectinib Savolitinib with Anlotinib PR , ongoing None reported 4 Male 67 Yes cT2N3M1c Thoracic vertebral, brain 3.3 PD-L1 ( TPS : 85% ) TP53 mutation; BRCA2 mutation; NF2 mutation; Combined immunochemotherapy Savolitinib, with sindilimab PR , ongoing Interstitial pneumonia

|||||||||| TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon, Opdivo (nivolumab) / BMS
A Phase I Open-label Study Ofnimotuzumab with Nivolumab in Advanced Non-Small Cell Lung Cancer or Head and Neck Squamous Cell Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2151;
Conclusions : Asymptomatic troponin elevation was seen with this combination treatment. While there were no clinically significant adverse cardiac outcomes, further development was terminated due to competitive landscape.

|||||||||| Tyvyt (sintilimab) / Eli Lilly
Down-Stage To Thoracic Surgery after Neoadjuvant Immunochemotherapy (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2115;
During the next 7 months of follow-up, no recurrence or metastasis was found. Conclusions : Neoadjuvant therapy may have potential to simplify surgical treatment, which means down-stage to thoracic surgery, but benefit patients with the same oncology effect, negative margin, and better perioperative outcome.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD), Tecentriq (atezolizumab) / Roche
Outpatient Treatment Strategies for Grade 3-4 Immune-Mediated Hepatitis in Patients with Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2114;
Further immunosuppressive intervention with mycophenolate mofetil (MMF) achieves resolution in over 80% of cases...Carboplatin + Etoposide + Atezolizumab...Outpatient management with methylprednisolone 250 mg iv for 3 days in day-hospital, and 30 mg/day of oral prednisone after bolus...Carboplatin + Etoposide + Atezolizumab...Carboplatin+ Pemetrexed+ Pembrolizumab every 21 days...This approach facilitates expedited immunosuppressive escalation for steroid-refractory immune-mediated toxicities, particularly immune-related hepatitis, where MMF emerges as a preferred adjunct. Further research is essential to elucidate optimal dosing and cessation protocols for immunosuppressive therapy.

|||||||||| Opdivo (nivolumab) / BMS
Low-Dose Nivolumab in Advanced NSCLC; Light at the End of the Tunnel (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2113;
Conclusions : Low-dose nivolumab can be effective in advanced NSCLC and can be an option to reduce financial toxicity. The efficacy of low-dose nivolumab is comparable with minimal adverse events.

|||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene
Therapeutic Efficacy of Immunotherapy and Chemotherapy in Metastatic Nuclear Protein in Testis Carcinoma with NUTM1::NSD3 Mutation Originating from the Bronchus: A Case Report (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2112;
Conclusions : This case highlights the potential therapeutic benefit of combining immunotherapy and chemotherapy as first-line treatment for metastatic NUTM1::NSD3 NC. Our findings suggest that immunotherapy may confer clinical benefits for NC patients with specific mutation profiles.

|||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene
Intrapleural Plus Systemic Tislelizumab Injection Combined Chemotherapy as Second-Line Treatment in a Case of RET Gene Fusion-Positive Lung Adenocarcinoma Presenting Refractory Malignant Pleural Effusion (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2111;
Conclusions : This case contributes to propose intrapleural immunotherapy as a feasible treatment option and intrapleural PD-1inhibitor bridging to systemic immunotherapy may represent a promising approach in NSCLC treatment. As with other potential applications of immunotherapy, immune biomarkers need to be better understood to aid in selection of this therapy.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Immune-Related Myasthenia Gravis in Patients with NSCLC: A Case Series (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2110;
2021. Abbreviation: AChEI, acetylcholinesterase inhibitor; CT, computerized tomography; ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; MG, myasthenia gravis; MGFA, Myasthenia Gravis Foundation of America; MRI, magnetic resonance imaging; PD-L1, programmed death-ligand 1; RNS, repetitive nerve stimulation

|||||||||| Opdivo (nivolumab) / BMS, RS5614 / Renascience
An Investigator-Initiated Phase II Study of Combination Treatment of Nivolumab and TM5614, A PAI-1 Inhibitor for Previously Treated NSCLC (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2108;
The study protocol conformed to the ethical principles outlined in the Declaration of Helsinki. All patients will provide written informed consent prior to enrollment.

|||||||||| Kaitanni (cadonilimab) / Akesobio
A Phase II Study of Cadonilimab Plus Chemotherapy as First-Line Treatment for PD-L1-Negative Advanced Non-Small Cell Lung Cancer:LungCadX (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2107;
Exploratory objective was to assess blood/tumor/urine/faeces tissue for potential biomarkers. Adverse events will be monitored throughout the trial and graded according to the CTCAE v5.0.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD)
The Impact of Body Mass Index on Immune-Related Adverse Events and Outcomes in Patients with Lung Cancer: A Real-World Study (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2100;
Pembrolizumab was the most often used ICI agent (67.2%)...Baseline BMI was found to have no significant impact on the efficacy of ICIs in lung cancer. Future studies with larger sample sizes are warranted to validate these findings.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
Body Mass Index and Genetic Association in Durable Responders to Immunotherapy in Metastatic Non-Small Cell Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2097;
Table 1. Baseline and Treatment-Related Characteristics Durable responders (n=67) Non-responders (n=257) Total (n=324 P-value Age, median (IQR) 66 (59-73.4) 67 (61-75) 66 (60-74 <65 29 (43.3%) 110 (42.8%) 139 (42.9%) 0.94 ?65 38 (56.7%) 147 (57.2%) 185 (57.1%) Sex Male 36 (53.7%) 140 (54.5%) 176 (54.3%) 0.91 Female 31 (46.3%) 117 (45.5%) 148 (45.7%) Race White/others 17 (25.4%) 83 (32.3%) 100 (30.9%) 0.15 Black 33 (49.3%) 93 (36.2%) 126 (38.9%) Hispanic 17 (25.4%) 81 (31.5%) 98 (30.2%) BMI, median (IQR) 25.2 (21.6-29.3) 22.6 (20.1-26.6) 23.0 (20.3-27.3) 0.01 BMI<25 34 (50.7%) 169 (65.8%) 203 (62.7%) 0.02 BMI?25 33 (49.3%) 88 (34.2%) 121 (37.3%) Smoking history Nerver Smoker 3 (4.5%) 28 (10.9%) 31 (9.6%) 0.11 Smoker 64 (95.5%) 229 (89.1%) 293 (90.4%) ECOG 0-1 57 (85.1%) 154 (59.9%) 211 (65.1%) 0.000 ?2 10 (14.9%) 103 (40.1%) 113 (34.9%) Histology Non-squamous 57 (85.1%) 208 (80.9%) 265 (81.8%) 0.43 Squamous cell carcinoma 10 (14.9%) 49 (19.1%) 59 (18.2%) Brain metastasis Yes 20 (29.9%) 65 (25.3%) 85 (26.2%) 0.45 No 47 (70.1%) 192 (74.7%) 239 (73.1%) Line of IO First line 50 (74.6%) 198 (77.0%) 248 (76.5%) 0.68 Second and subsequent line 17 (25.4%) 59 (23.0%) 76 (23.5%) Type of IO Pembrolizumab 56 (83.6%) 216 (84.0%) 272 (84.0%) 0.96 Nivolumab 9 (13.4%) 32 (12.5%) 41 (12.7%) Others 2 (3.0%) 9 (3.5%) 11 (3.4%) IO with chemotheray Yes 27 (40.3%) 125 (48.6%) 152 (46.9%) 0.22 No 40 (59.7%) 132 (51.4%) 172 (53.1%) PD-L1 (%) <50 32 (52.5%) 141 (61.3%) 173 (59.5%) 0.21 ?50 29 (47.5%) 89 (38.7%) 118 (40.5%) TMB N/A 49 (73.1%) 194 (75.5%) 243 (75.0%) <10 7 (38.9%) 33 (52.4%) 40 (49.4%) 0.31 ?10 11 (61.1%) 30 (47.6%) 41 (50.6%) Actionable alteration N/A 25 (37.3%) 113 (44.0%) 138 (42.6%) Yes 8 (19.0%) 36 (25.0%) 44 (23.7%) 0.42 No 34 (81.0%) 108 (75.0%) 142 (76.3%) iAEs Yes 22 (32.8%) 66 (25.7%) 88 (27.2%) 0.24 No 45 (67.2%) 191 (74.3%) 236 (72.8%)

|||||||||| Anniko (penpulimab) / Akesobio, Sino Biopharm
Efficacy and Safety of Penpulimab-Containing Regimens for Advanced Malignant Solid Tumors That Have Failed Immunotherapy: A Real World Study. (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2092;
Information about NSCLC patients No. PD-L1 expression ECOG PS PFS-months PFS status Best objective response 1 50% 1 25.9 0 SD 2 <1% 1 21.9 0 SD 3 ?1% 1 2.4 1 PD 4 NE 1 18.1 1 SD 5 1%-49% 1 17.1 1 SD 6 ?1% 1 2.6 0 SD 7 NE 0 5.3 1 SD

|||||||||| Imfinzi (durvalumab) / AstraZeneca
Real-Life Study of Patients with Unresectable Stage III Non-Small Cell Lung Cancer Treated with Chemoradiotherapy Followed by Durvalumab. (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2091;
Conclusions : Encouraging results are observed in terms of relapse-free survival and treatment response. Despite limited evidence in our region, the majority of patients treated with durvalumab experienced prolonged relapse-free survival.

|||||||||| Opdivo (nivolumab) / BMS
Evaluating Efficacy and Safety of Nivolumab in Pretreated NSCLC Patients: Insights from Real-World Data (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2090;
Since the introduction of the first immunotherapy as a second-line treatment for non-small cell lung cancer (NSCLC) in 2014, nivolumab has demonstrated superior efficacy compared to docetaxel, particularly in advanced squamous and nonsquamous NSCLC with a median overall survival (mOS) of 12.2 months for nonsquamous and 9.2 months for squamous NSCLC...Although our patients were heavily pretreated, there was a clear survival benefit of nivolumab treatment compared to available extensive clinical trial data. We observed that the development of side effects was a significant factor in better overall survival and progression-free survival.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Consensus on Maintenance Therapy after a First-Line Pembrolizumab-Containing Regimen in Advanced/metastatic NSCLC (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2089;
Conclusions : In this study, panel oncologists concurred on a 1LMT strategy, but differed on recommended 1LMT when PD-L1 levels were <50% and on preferred pemetrexed duration. Given a lack of 1LMT treatment guidelines for patients with a/mNSCLC without actionable genomic alterations, these results provide useful recommendations for treating physicians.

|||||||||| REAL-IMPACT: Real-World Effectiveness of Immunotherapy in PD-L1 Negative Advanced NSCLC - A Multicenter Cohort Study in Argentina (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2087;
The frequency of grade 3 adverse events were similar to those reported in clinical trials. Longer follow-up is needed to evaluate the benefits of OS.

|||||||||| Comparing Outcomes and Adverse Events in Lung Cancer Immunotherapy: The Impact of Smoking Status (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2086;
The interesting observation in our study is that patients who are active smokers tend to have a lesser number of immunotherapy-related adverse events compared to past smokers and non-smokers. We also identified a proportion of patients using topical steroids without any documentation of dermatitis, likely underreporting dermatological immune-related side effects.

|||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene
Efficacy and Influencing Clinical Factors of Tislelizumab Combined with Chemotherapy Plus Bone-Targeted Agents for NSCLC Bone Metastasis (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2081;
For the safety outcomes, mild immune-related AEs such as rash, pruritus,hypothyroidism, pneumonitis were experienced and none ?3irAE occurred. Conclusions : This study demonstrated that tislelizumab combined with platinum-based chemotherapy plus bone-targeted agents is a promising option in the first line therapy for advanced NSCLC patients with bone metastasis and baseline levels of NLR and PLR were important and associated with PFS outcomes of immunotherapy.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Tecentriq (atezolizumab) / Roche
Immunotherapy in Metastatic Pulmonary Lymphoepithelioma-Like Carcinoma (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2071;
The immunotherapy used in 1st line were mainly pembrolizumab(pembrolizumab =7, atezolizumab = 1)...An exploratory analysis in subsequent line patients shows trend towards longer median PFS and OS for patients receiving atezolizumab than nivolumab (mPFS 7.73 vs 3.50 months, p=0.231; mOS 22.2 vs 8.00 months, p=0.114)...Conclusions : The observed mPFS and mOS in our cohort of pLELC treated with immunotherapy were numerically similar to those observed in major NSCLC trials, including KEYNOTE-024, Checkmate 057 and OAK. As driver mutation was rarely seen in pLELC, IO monotherapy or combination could become the mainstream treatment as in NSCLC lacking driver mutation.

|||||||||| Opdivo (nivolumab) / BMS, Tecentriq (atezolizumab) / Roche
Use of Immune Checkpoint Inhibitors in Advanced NSCLC Cases with Very Poor ECOG-PS: A Real World Experience. (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2069;
Conclusions : ICI remain a viable treatment option in patients of advanced NSCLC with very poor ECOG-PS. The relative safety of ICI over chemotherapy may provide an additional tool to Best Supportive Care treatment recommendation for this specific subgroup.



	Diseases Companies Products Productz Mechanisms of Action Sites